Infectious disease experts say the mRNA technology used in vaccines is safe, and they credit its development during the first ...

With a market cap of $10.7 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development of ...

The US Department of Health and Human Services is to cancel contracts and pull funding for some vaccines that are being developed to fight respiratory viruses like Covid-19 and the flu. Robert F ...

The Department of Health and Human Services is going to cancel contracts and pull funding for these projects, Robert F ...

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing a phase 1 vaccine candidate to expand its RSV pipeline beyond mRNA.

A new UK study shows that vaccinating pregnant women against RSV has led to a staggering 72% drop in hospitalizations of newborns with severe lung infections. By passing virus-fighting antibodies ...

Investigators attempted to determine the burden of RSV-associated disease in the pre-vaccine era to characterize the impact of vaccination on older populations in the US.

RSV-Related Hospitalizations and Comorbidities: Two Surprises Here —A recent study examined several broad categories of comorbidities in an attempt to determine which ones correlated with ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.